{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:52:10Z","timestamp":1791384730767,"version":"4.3.3"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Salmonella Typhi is an invasive pathogen with sustained bacteraemia and intracellular persistence, requiring therapy that achieves systemic exposure and intracellular penetration. Clinical efficacy should remain central to therapeutic decision-making, while pharmacokinetic\/pharmacodynamic (PK\/PD) analyses provide complementary insights into dose optimization and the pharmacological limitations of candidate therapies. Oral therapy remains central to typhoid fever management, particularly in South and Southeast Asia, where most patients are managed in the outpatient setting. However, the emergence of MDR and extensively drug-resistant (XDR) S. Typhi has substantially narrowed the available oral treatment options. Azithromycin remains the only widely available oral agent with established clinical efficacy, but emerging resistance threatens its continued utility. Several alternative oral agents, including mecillinam, faropenem, tebipenem, fosfomycin and \u03b2-lactam\/\u03b2-lactamase inhibitor combinations, demonstrate favourable in vitro activity against S. Typhi. However, robust clinical efficacy and contemporary PK\/PD data are lacking to support their use against MDR and XDR S. Typhi. Addressing these evidence gaps through integrated PK\/PD investigations and prospective clinical trials will be essential to expand the oral therapeutic armamentarium for typhoid fever.<\/jats:p>","DOI":"10.1093\/jac\/dkag332","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:49:03Z","timestamp":1790164143000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond susceptibility: pharmacokinetic and pharmacodynamic constraints of existing oral antibiotics in extensively drug-resistant typhoid fever"],"prefix":"10.1093","volume":"81","author":[{"given":"Yamuna Devi","family":"Bakthavatchalam","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Christian Medical College , Vellore ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5115-067X","authenticated-orcid":false,"given":"Priscilla","family":"Rupali","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Christian Medical College , Vellore ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"John","sequence":"additional","affiliation":[{"name":"Community Medicine, Christian Medical College , Vellore ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Walia","sequence":"additional","affiliation":[{"name":"Division of Descriptive Research, Indian Council of Medical Research , New Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant","family":"Nagvekar","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Lilavati Hospital , Mumbai ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Christian Medical College , Vellore ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2026100709584416200_dkag332-B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2025.100237","article-title":"The interplay between Salmonella and host: mechanisms and strategies for bacterial survival","volume":"4","author":"Zhao","year":"2025","journal-title":"Cell Insight"},{"key":"2026100709584416200_dkag332-B2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.imlet.2017.07.006","article-title":"Salmonella infection: interplay between the bacteria and host immune system","volume":"190","author":"Kurtz","year":"2017","journal-title":"Immunol Lett"},{"issue":"Suppl 1","key":"2026100709584416200_dkag332-B3","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1093\/ofid\/ofad179","article-title":"What should we be recommending for the treatment of enteric fever?","volume":"10","author":"Parry","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026100709584416200_dkag332-B4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010452.pub2","article-title":"Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins","volume":"11","author":"Kuehn","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100709584416200_dkag332-B5","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.1038\/s41467-023-42353-9","article-title":"Assessing the global risk of typhoid outbreaks caused by extensively drug resistant Salmonella Typhi","volume":"14","author":"Walker","year":"2023","journal-title":"Nat Commun"},{"key":"2026100709584416200_dkag332-B6","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00105-18","article-title":"Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins","volume":"9","author":"Klemm","year":"2018","journal-title":"mBio"},{"key":"2026100709584416200_dkag332-B7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0924-8579(02)00187-5","article-title":"Disposition and intracellular activity of azithromycin in human THP-1 acute monocytes","volume":"20","author":"Hall","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"2026100709584416200_dkag332-B8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25 Suppl A","author":"Foulds","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"2026100709584416200_dkag332-B9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/BF01975832","article-title":"The pharmacokinetics of azithromycin and their clinical significance","volume":"10","author":"Lode","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026100709584416200_dkag332-B10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1128\/AAC.43.1.163","article-title":"Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1500 milligrams, given over a 3- or 5-day period in healthy subjects","volume":"43","author":"Amsden","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709584416200_dkag332-B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008682","article-title":"Response of extensively drug resistant Salmonella Typhi to treatment with meropenem and azithromycin, in Pakistan","volume":"14","author":"Qureshi","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2026100709584416200_dkag332-B12","author":"Centers for Disease Control and Prevention"},{"key":"2026100709584416200_dkag332-B13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/j.1469-0691.2011.03552.x","article-title":"Treatment of typhoid fever in the 21st century: promises and shortcomings","volume":"17","author":"Butler","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2026100709584416200_dkag332-B14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/jac\/44.2.243","article-title":"Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India","volume":"44","author":"Butler","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2026100709584416200_dkag332-B15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1128\/AAC.37.8.1572","article-title":"Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial","volume":"37","author":"Islam","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709584416200_dkag332-B16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/clinids\/4.2.551","article-title":"Response of typhoid fever caused by chloramphenicol-susceptible and chloramphenicol-resistant strains of Salmonella Typhi to treatment with trimethoprim-sulfamethoxazole","volume":"4","author":"Butler","year":"1982","journal-title":"Rev Infect Dis"},{"key":"2026100709584416200_dkag332-B17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/infdis\/132.6.630","article-title":"Comparison of trimethoprim-sulfamethoxazole and amoxicillin in therapy of chloramphenicol-resistant and chloramphenicol-sensitive typhoid fever","volume":"132","author":"Gilman","year":"1975","journal-title":"J Infect Dis"},{"key":"2026100709584416200_dkag332-B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1865","article-title":"A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: meta-analysis","volume":"338","author":"Thaver","year":"2009","journal-title":"BMJ"},{"key":"2026100709584416200_dkag332-B19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.trstmh.2003.10.014","article-title":"The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam","volume":"98","author":"Parry","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2026100709584416200_dkag332-B20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.trstmh.2004.08.007","article-title":"A randomized comparison of oral chloramphenicol versus ofloxacin in the treatment of uncomplicated typhoid fever in Laos","volume":"99","author":"Phongmany","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2026100709584416200_dkag332-B21","doi-asserted-by":"publisher","first-page":"e1163","DOI":"10.1371\/journal.pntd.0001163","article-title":"The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy","volume":"5","author":"Parry","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2026100709584416200_dkag332-B22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s101560070016","article-title":"Comparative uptake of grepafloxacin and ciprofloxacin by a human monocytic cell line, THP-1","volume":"6","author":"Hara","year":"2000","journal-title":"J Infect Chemother"},{"key":"2026100709584416200_dkag332-B23","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1128\/AAC.43.6.1441","article-title":"Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance","volume":"43","author":"Girgis","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709584416200_dkag332-B24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1128\/AAC.00447-06","article-title":"Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever","volume":"51","author":"Parry","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709584416200_dkag332-B25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1086\/382359","article-title":"Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents","volume":"38","author":"Frenck","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026100709584416200_dkag332-B26","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1086\/317450","article-title":"Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children","volume":"31","author":"Frenck","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2026100709584416200_dkag332-B27","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1128\/CMR.00002-15","article-title":"Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections","volume":"28","author":"Crump","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2026100709584416200_dkag332-B28","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.7860\/JCDR\/2012\/4702.2631","article-title":"A comparative study of efficacy and safety of azithromycin and ofloxacin in uncomplicated typhoid fever: a randomised, open labelled study","volume":"6","author":"Chandey","year":"2012","journal-title":"J Clin Diagn Res"},{"key":"2026100709584416200_dkag332-B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007868","article-title":"Molecular mechanism of azithromycin resistance among typhoidal Salmonella strains in Bangladesh identified through passive pediatric surveillance","volume":"13","author":"Hooda","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2026100709584416200_dkag332-B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006380","article-title":"Open label comparative trial of mono versus dual antibiotic therapy for typhoid fever in adults","volume":"12","author":"Zmora","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2026100709584416200_dkag332-B31","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03481-20","article-title":"Tracking the emergence of azithromycin resistance in multiple genotypes of typhoidal Salmonella","volume":"12","author":"Sajib","year":"2021","journal-title":"mBio"},{"key":"2026100709584416200_dkag332-B32","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00215-20","article-title":"A race against time: reduced azithromycin susceptibility in Salmonella enterica serovar Typhi in Pakistan","volume":"5","author":"Iqbal","year":"2020","journal-title":"mSphere"},{"key":"2026100709584416200_dkag332-B33","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1093\/cid\/ciaa1773","article-title":"Spontaneous emergence of azithromycin resistance in independent lineages of Salmonella Typhi in Northern India","volume":"72","author":"Carey","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026100709584416200_dkag332-B34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/infdis\/158.4.742","article-title":"Randomized treatment of patients with typhoid fever by using ceftriaxone or chloramphenicol","volume":"158","author":"Islam","year":"1988","journal-title":"J Infect Dis"},{"key":"2026100709584416200_dkag332-B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0013067","article-title":"XDR typhoid in Pakistan: a threat to global health security and a wake-up call for antimicrobial stewardship","volume":"19","author":"Abdullah","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"key":"2026100709584416200_dkag332-B36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/287440a0","article-title":"Control of natural resistance to Salmonella typhimurium and Leishmania donovani in mice by closely linked but distinct genetic loci","volume":"287","author":"O'Brien","year":"1980","journal-title":"Nature"},{"key":"2026100709584416200_dkag332-B37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1084\/jem.20031319","article-title":"Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+\/+ mice and can be reactivated by IFNgamma neutralization","volume":"199","author":"Monack","year":"2004","journal-title":"J Exp Med"},{"key":"2026100709584416200_dkag332-B38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.chom.2010.09.003","article-title":"A mouse model for the human pathogen Salmonella Typhi","volume":"8","author":"Song","year":"2010","journal-title":"Cell Host Microbe"},{"key":"2026100709584416200_dkag332-B39","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2026100709584416200_dkag332-B40","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1128\/AAC.01301-08","article-title":"Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis","volume":"53","author":"Cheng","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709584416200_dkag332-B41","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02167-21","article-title":"In vitro time-kill studies of trimethoprim\/sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli using cation-adjusted Mueller-Hinton broth and ISO-Sensitest broth","volume":"66","author":"Lasko","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709584416200_dkag332-B42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/jac\/26.5.689","article-title":"Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella Typhi within human monocyte-derived macrophages","volume":"26","author":"Chang","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"2026100709584416200_dkag332-B43","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00042-24","article-title":"The oral penems and carbapenems","volume":"38","author":"Sayood","year":"2025","journal-title":"Clin Microbiol Rev"},{"key":"2026100709584416200_dkag332-B44","author":"Aurobindo Pharma - Milpharm Ltd","year":"2024"},{"issue":"2A","key":"2026100709584416200_dkag332-B45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/0002-9343(83)90098-0","article-title":"Review of clinical experience with amdinocillin monotherapy and comparative studies","volume":"75","author":"Demos","year":"1983","journal-title":"Am J Med"},{"key":"2026100709584416200_dkag332-B46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/BF01645219","article-title":"The combination of pivmecillinam and pivampicillin in the treatment of enteric fever","volume":"12","author":"Tanphaichitra","year":"1984","journal-title":"Infection"},{"key":"2026100709584416200_dkag332-B47","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1093\/cid\/ciaf280","article-title":"Pivmecillinam for treatment of uncomplicated urinary tract infection: new efficacy analysis","volume":"81","author":"Lodise","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026100709584416200_dkag332-B48","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01824-24","article-title":"New perspectives on antimicrobial agents: pivmecillinam","volume":"69","author":"Hawkins","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709584416200_dkag332-B49","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03441-22","article-title":"Pharmacokinetic\/pharmacodynamic determination of systemic MIC breakpoints for intermittent, extended, and continuous infusion dosage regimens of mecillinam","volume":"11","author":"Koumaki","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026100709584416200_dkag332-B50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1345\/aph.1G232","article-title":"Faropenem medoxomil","volume":"42","author":"Gettig","year":"2008","journal-title":"Ann Pharmacother"},{"key":"2026100709584416200_dkag332-B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115662","article-title":"Probability of target attainment of oral antimicrobials for Escherichia coli and Klebsiella pneumoniae based on Monte Carlo simulations","volume":"103","author":"Yamada","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026100709584416200_dkag332-B52","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1093\/jac\/dkab326","article-title":"Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi","volume":"76","author":"Mylona","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026100709584416200_dkag332-B53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2026100709584416200_dkag332-B54","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/cid\/cix652","article-title":"Successful therapy of a multidrug-resistant extended-Spectrum \u03b2-lactamase-producing and fluoroquinolone-resistant Salmonella enterica subspecies enterica serovar Typhi infection using combination therapy of meropenem and fosfomycin","volume":"65","author":"Kleine","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026100709584416200_dkag332-B55","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections","volume":"34","author":"Roussos","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2026100709584416200_dkag332-B56","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02498-16","article-title":"Pharmacodynamic evaluation of fosfomycin against Escherichia coli and Klebsiella spp. from urinary tract infections and the influence of pH on fosfomycin activities","volume":"61","author":"Fedrigo","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1-2","key":"2026100709584416200_dkag332-B57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000069787","article-title":"Intracellular activity of fosfomycin against two distinct enteropathogenic bacteria, Salmonella enterica and Listeria monocytogenes, alive inside host cells","volume":"49","author":"Okada","year":"2003","journal-title":"Chemotherapy"},{"key":"2026100709584416200_dkag332-B58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/jac\/15.6.723","article-title":"Inability of gentamicin and fosfomycin to eliminate intracellular Enterobacteriaceae","volume":"15","author":"Kihlstr\u00f6m","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"2026100709584416200_dkag332-B59","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/jac\/dkw226","article-title":"Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints","volume":"71","author":"de Velde","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026100709584416200_dkag332-B60","doi-asserted-by":"publisher","first-page":"207","DOI":"10.12688\/wellcomeopenres.16801.1","article-title":"Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol","volume":"6","author":"Giri","year":"2021","journal-title":"Wellcome Open Res"},{"key":"2026100709584416200_dkag332-B61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/jac\/46.6.973","article-title":"Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo","volume":"46","author":"Johansen","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2026100709584416200_dkag332-B62","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ijantimicag.2004.02.030","article-title":"In vitro antagonism between beta-lactam and macrolide in Streptococcus pneumoniae: how important is the antibiotic order?","volume":"24","author":"Ortega","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"2026100709584416200_dkag332-B63","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1128\/AAC.47.3.1151-1153.2003","article-title":"Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro","volume":"47","author":"Lin","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100709584416200_dkag332-B64","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3201\/eid2911.230499","article-title":"Case of carbapenem-resistant Salmonella Typhi infection, Pakistan, 2022","volume":"29","author":"Nizamuddin","year":"2023","journal-title":"Emerg Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag332\/71665678\/dkag332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag332\/71665678\/dkag332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:58:50Z","timestamp":1791381530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag332\/8875742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag332","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,6]]},"article-number":"dkag332"}}